Cardio-Oncology Risk Assessment and Management in Patients Receiving Pertuzumab and Trastuzumab: Case Report and Literature Review

Pertuzumab significantly improved the rates of invasive-disease–free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab chemotherapy. Pertuzumab is a HER2/neu receptor antagonist is indicated by Food and Drug Administration for: 1) Use in combination with trastuzumab and docetaxel for treatment of patients with HER2positive MBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease; or 2) Use in combination with trastuzumab and docetaxel as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. Pertuzumab use can be associated with cardiac-related adverse events, including CHF and decline in LVEF. Patients should be screened into low and high-risk categories. Prior to initiating this combination therapy, a detailed clinical history of cardiovascular risk factors is indicated along with protocol-driven periodic TTE monitoring during therapy. Cardiology Research and Cardiovascular Medicine Medepalli LC, et al. Cardiolog Res Cardiovasc Med 7: 170. www.doi.org/10.29011/2575-7083.100170 www.gavinpublishers.com